The Use of Positron Emission Computed Tomography and Computed Tomography in the Treatment of Gynecological Malignant Tumor

2020 ◽  
Vol 10 (9) ◽  
pp. 2062-2066
Author(s):  
Lang Yang ◽  
Xiaoxia Hu.
Keyword(s):  
Computed Tomography ◽  
Comprehensive Treatment ◽  
Emission Computed Tomography ◽  
Conventional Imaging ◽  
Ct Diagnosis ◽  
Positron Emission ◽  
Pet Ct ◽  
Before And After ◽  
Predictive Rate ◽  
Fdg Pet Ct

Objective: Investigating the value of 18Fluorine-Fluorodesoxyglucose (18F-FDG) positron emission computed tomography/computed tomography (PET/CT) before and after the comprehensive treatment of gynecological malignant tumors is the study purpose. Method: In this study, the patients with gynecological malignant tumor who are examined by 18F-FDG PET/CT test are taken as the study objects, supplemented by image fusion algorithm to achieve the best fusion effect. At the same time, routine imaging examination is performed and confirmed by histopathology. Before and after comprehensive treatment, in terms of PET/CT, its predictive rate of positive as well as negative, sensitivity, specificity as well as accuracy are compared with conventional imaging. Results: Before comprehensive treatment, the positive predictive rate of PET/CT diagnosis is 100%, the sensitivity is 95.00%, and the accuracy is 95.00%. The positive predictive rate of conventional imaging diagnosis is 100%, the sensitivity is 73.75%, and the accuracy is 73.75%. In terms of the PET/CT sensitivity as well as accuracy, conventional imaging is lower than that of it. After comprehensive treatment, the positive predictive rate of PET/CT diagnosis is 96.30%, the negative predictive rate is 100.00%, the sensitivity is 100.00%, the specificity is 92.86%, and the accuracy is 95.50%. The positive predictive rate of conventional imaging diagnosis is 94.87%, the negative predictive rate is 68.29%, the sensitivity is 74.00%, the specificity is 93.33%, and the accuracy is 81.25%. In terms of the above indexes, conventional imaging is lower than PET/CT diagnosis. Conclusion: When it is compared with conventional imaging, 18F-FDG PET/CT has higher accuracy. Besides, it is more comprehensive when diagnosing gynecological cancer before and after comprehensive treatment, which is worthy of clinical promotion.

FDG-PET/CT Assessment of Pulmonary Sarcoidosis: A Guide for Internists

2018 ◽  
Vol 15 (1) ◽  
pp. 21-25 ◽  
Author(s):  
Marco Tana ◽  
Silvio di Carlo ◽  
Marcello Romano ◽  
Massimo Alessandri ◽  
Cosima Schiavone ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Fdg Pet ◽  
Correct Diagnosis ◽  
Pulmonary Sarcoidosis ◽  
High Resolution Computed Tomography ◽  
Inflammatory Conditions ◽  
Positron Emission ◽  
Pet Ct ◽  
Noncaseating Granulomas ◽  
Fdg Pet Ct

Background:18F-fluorodeoxyglucose positron emission tomography integrated with computed tomography (18-F-FDG-PET/CT) is getting wide consensus in the diagnosis and staging of neoplastic disorders and represents a useful tool in the assessment of various inflammatory conditions. </P><P> Discussion: Sarcoidosis is an uncommon disease characterized by the systemic formation of noncaseating granulomas. Lungs are the sites most often affected, and investigation with high resolution computed tomography and biopsy is essential to achieve a correct diagnosis. 18-F-FDGPET/ CT is effective in the assessment of pulmonary sarcoidosis by demonstrating pulmonary and extrathoracic involvement and findings correlate well with pulmonary function in patients affected.Conclusion:This review would illustrate the usefulness and limits of 18-F-FDG-PET/CT in the assessment of pulmonary sarcoidosis.

scholarly journals A Nordic survey of CT doses in hybrid PET/CT and SPECT/CT examinations

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Natalie A. Bebbington ◽  
Bryan T. Haddock ◽  
Henrik Bertilsson ◽  
Eero Hippeläinen ◽  
Ellen M. Husby ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Single Photon ◽  
Photon Emission ◽  
Emission Computed Tomography ◽  
Single Photon Emission ◽  
Positron Emission ◽  
Pet Ct ◽  
Clinical Purpose ◽  
Single Photon Emission Computed ◽  
Photon Emission Computed Tomography

Abstract Background Computed tomography (CT) scans are routinely performed in positron emission tomography (PET) and single photon emission computed tomography (SPECT) examinations globally, yet few surveys have been conducted to gather national diagnostic reference level (NDRL) data for CT radiation doses in positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/computed tomography (SPECT/CT). In this first Nordic-wide study of CT doses in hybrid imaging, Nordic NDRL CT doses are suggested for PET/CT and SPECT/CT examinations specific to the clinical purpose of CT, and the scope for optimisation is evaluated. Data on hybrid imaging CT exposures and clinical purpose of CT were gathered for 5 PET/CT and 8 SPECT/CT examinations via designed booklet. For each included dataset for a given facility and scanner type, the computed tomography dose index by volume (CTDIvol) and dose length product (DLP) was interpolated for a 75-kg person (referred to as CTDIvol,75kg and DLP75kg). Suggested NDRL (75th percentile) and achievable doses (50th percentile) were determined for CTDIvol,75kg and DLP75kg according to clinical purpose of CT. Differences in maximum and minimum doses (derived for a 75-kg patient) between facilities were also calculated for each examination and clinical purpose. Results Data were processed from 83 scanners from 43 facilities. Data were sufficient to suggest Nordic NDRL CT doses for the following: PET/CT oncology (localisation/characterisation, 15 systems); infection/inflammation (localisation/characterisation, 13 systems); brain (attenuation correction (AC) only, 11 systems); cardiac PET/CT and SPECT/CT (AC only, 30 systems); SPECT/CT lung (localisation/characterisation, 12 systems); bone (localisation/characterisation, 30 systems); and parathyroid (localisation/characterisation, 13 systems). Great variations in dose were seen for all aforementioned examinations. Greatest differences in DLP75kg for each examination, specific to clinical purpose, were as follows: SPECT/CT lung AC only (27.4); PET/CT and SPECT/CT cardiac AC only (19.6); infection/inflammation AC only (18.1); PET/CT brain localisation/characterisation (16.8); SPECT/CT bone localisation/characterisation (10.0); PET/CT oncology AC only (9.0); and SPECT/CT parathyroid localisation/characterisation (7.8). Conclusions Suggested Nordic NDRL CT doses are presented according to clinical purpose of CT for PET/CT oncology, infection/inflammation, brain, PET/CT and SPECT/CT cardiac, and SPECT/CT lung, bone, and parathyroid. The large variation in doses suggests great scope for optimisation in all 8 examinations.

POSITRON EMISSION TOMOGRAPHY WITH 18F -FDG IN THE DIAGNOSIS OF PROSTHETIC HEART VALVE ENDOCARDITIS

2021 ◽  
Vol 5 (1) ◽  
pp. 1151-1160
Author(s):  
A.S. Lukashevich ◽  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Prosthetic Heart Valve ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose. The purpose of the article is to evaluate the diagnostic significance of positron emission tomography / computed tomography with 18F -fluorodeoxyglucose (18F -FDG PET/CT) for the diagnosis of prosthetic endocarditis. Methods of research. The study included 82 patients with suspected prosthetic endocarditis in accordance with the criteria proposed by Duke University [1-5]. The patients received hospital treatment at the State Institution RSPC "Cardiology" from January 2016 to March 2021. The study was of a prospective, non-randomized, single-center cohort design. The duration of the monitor period was 12 months from the moment of patients’ inclusion in the study. Whole-body positron emission tomography / computed tomography (PET/CT) examinations were performed in 82 patients. 27 patients were selected for surgical treatment. Conservative treatment group included 16 patients. 27 patients were selected into the observation group, they were suspected to have prosthetic heart valve infection in the primary referral and underwent PET/CT scanning, according to which the diagnosis of prosthetic endocarditis was excluded. The event under the study did not develop in this group during the year of observation. Results and conclusion. The history of infective endocarditis was not statistically significant and did not increase the risk of developing prosthetic endocarditis in the sample presented. The Duke criteria are less reliable in establishing the diagnosis of prosthetic endocarditis. The median number of days from the date of the first prosthesis implantation to the onset of prosthetic endocarditis was about 4 years. This study revealed that the development of the infectious process in the area of the prosthesis was noted in a more distant postoperative period compared to literature data. Histological confirmation of infection was noted in 100% (27 patients) of cases in reoperated patients. The presence of a more formidable complication such as valve ring abscess located mainly in the projection of the aortic valve ring was quite common in both groups. Presepsin and Interleukin-6 have a statistically significant (U = 394,50 p = 0,01 and U = 94,50 p = 0.004) value in the prognosis of prosthetic endocarditis. Considering the data obtained from ROC analysis, it can be said that the cut-off point at which it is possible to diagnose prosthetic endocarditis based on PETCT is 2.85. The presented methods for the interpretation of whole-body FDG-PET/CT images of patients with suspected infectious complications after cardiac surgery, as well as with the presence of prosthetic endocarditis, show high sensitivity and specificity.

Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis

2021 ◽  
pp. jrheum.210040
Author(s):  
Attila Feher ◽  
Nabil E. Boutagy ◽  
Evangelos K. Oikonomou ◽  
Stephanie Thorn ◽  
Yi-Hwa Liu ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Systemic Sclerosis ◽  
Myocardial Flow Reserve ◽  
Coronary Microvascular Dysfunction ◽  
Emission Computed Tomography ◽  
Flow Reserve ◽  
Positron Emission ◽  
Pet Ct ◽  
Myocardial Flow ◽  
Healthy Participants

Objective To investigate the association between Raynaud phenomenon (RP) and coronary microvascular dysfunction, we measured myocardial flow reserve (MFR) using positron emission tomography/computed tomography (PET/CT) in primary and secondary RP patients and controls. Methods RP patients, patient controls and healthy participants who underwent dynamic reststress 82-Rubidium PET/CT were studied. Differences in heart rate-blood pressure product corrected MFR and clinical predictors of reduced MFR (< 2.0) were determined. Results 49 RP patients (80% female, 65 ± 11 years): 11 primary RP, 18 systemic sclerosis (SSc) and 20 other autoimmune diseases (AID) (n=6 systemic lupus erythematosus, n=6 rheumatoid arthritis, n=4 overlap syndrome, n=2 Sjogren's syndrome, n=2 inflammatory arthritis), 49 matched patients without RP or AID (78% female, 64 ± 13 years) and 14 healthy participants (50% female, 35 ± 5 years) were studied. Primary RP patients, matched patient controls and healthy participants had comparable MFR. SSc-RP patients had significantly reduced MFR (1.62 ± 0.32) compared to matched patient controls (p=0.03, 2.06 ± 0.61) and to healthy participants (p=0.01, 2.22 ± 0.44). In multivariable logistic regression, SSc was an independent predictor of reduced MFR. We identified a correlation between time since AID diagnosis and MFR (r= -0.37; 95% CI: -0.61 to -0.09; p=0.01). Conclusion Our findings suggest that only secondary, not primary, RP is associated with reduced MFR, and that SSc-RP patients have reduced MFR compared to primary RP and other

scholarly journals Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer

2010 ◽  
Vol 28 (25) ◽  
pp. 3973-3978 ◽  
Author(s):  
Andrea B. Apolo ◽  
Jamie Riches ◽  
Heiko Schöder ◽  
Oguz Akin ◽  
Alisa Trout ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Bladder Cancer ◽  
Sensitivity And Specificity ◽  
Fdg Pet ◽  
Malignant Disease ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

Purpose Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) has been approved for imaging in many malignancies but not for bladder cancer. This study investigated the value of FDG-PET/CT imaging in the management of patients with advanced bladder cancer. Patients and Methods Between May 2006 and February 2008, 57 patients with bladder cancer at our center underwent FDG-PET/CT after CT (n = 52) or magnetic resonance imaging (MRI; n = 5). The accuracy of FDG-PET/CT was assessed using both organ-based and patient-based analyses. FDG-PET/CT findings were validated by either biopsy or serial CT/MRI. Clinician questionnaires performed before and after FDG-PET/CT assessed whether those scan results affected management. Results One hundred thirty-five individual lesions were evaluable in 47 patients for the organ-based analysis. Overall sensitivity and specificity were 87% (95% CI, 76% to 94%) and 88% (95% CI, 78% to 95%), respectively. In the patient-based analysis, malignant disease was correctly diagnosed in 25 of 31 patients, resulting in a sensitivity of 81% (95% CI, 63% to 93%). FDG-PET/CT was negative in 15 of 16 patients without malignant lesions for a specificity of 94% (95% CI, 71% to 100%). Pre- and post-PET surveys revealed that FDG-PET/CT detected more malignant disease than conventional CT/MRI in 40% of patients. Post-PET surveys showed that clinicians changed their planned management in 68% of patients based on the FDG-PET/CT results. Conclusion FDG-PET/CT has excellent sensitivity and specificity in the detection of metastatic bladder cancer and provides additional diagnostic information that enhances clinical management more than CT/MRI alone. FDG-PET/CT scans may provide better accuracy in clinical information for directing therapy.

scholarly journals 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings in Mucosa-Associated Lymphoid Tissue Lymphoma of the Larynx: A Case Report and Literature Review

2012 ◽  
Vol 40 (3) ◽  
pp. 1192-1206 ◽  
Author(s):  
K Zhao ◽  
Y-Z Luo ◽  
S-H Zhou ◽  
B-L Dai ◽  
X-M Luo ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Malt Lymphoma ◽  
Lymphoid Tissue ◽  
Immunohistochemical Analysis ◽  
Emission Tomography ◽  
Positron Emission ◽  
Laryngeal Mucosa ◽  
Pet Ct ◽  
Fdg Pet Ct

Laryngeal mucosa-associated lymphoid tissue (MALT) lymphoma is rare, with only 25 cases reported in the literature. This report presents a case of laryngeal MALT lymphoma in a 35-year-old female with a 6-year history of progressively worsening hoarseness. MALT lymphoma was diagnosed based on biopsy and immunohistochemical analysis. The patient received two cycles of cyclo-phosphamide + epirubicin + vincristine + prednisone (CHOP) chemo therapy, which was ineffective. 18F-fluoro deoxy glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) showed 18F-FDG accumulation in the larynx only and identified stage IE lymphoma. CHOP chemotherapy was terminated and the patient was treated with radiotherapy. After 3 months (total radiation dose 27 Gy), 18F-FDG PET/CT scan showed that the laryngeal lesion was in complete remission. A review of the literature on the MEDLINE®/PubMed® databases regarding laryngeal MALT lymphoma and the use of PET/CT found that radiotherapy is the firstline treatment for stage I and II MALT lymphoma.

Sign in / Sign up

Export Citation Format

Share Document